PTBP1 promotes tumorigenesis by regulating apoptosis and cell cycle in colon cancer.
This study implies that PTBP1 plays an important role in tumorigenesis of colon cancer. PMID: 30309622 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - October 8, 2018 Category: Cancer & Oncology Authors: Li X, Han F, Liu W, Shi X Tags: Bull Cancer Source Type: research

[Issues of oral targeted therapies in daily clinical practice: 5th edition of the congress of pharmacology of anticancer drugs].
Abstract Oral targeted therapies are a growing class of medication. After clinical trials conducted on a selected population, these molecules are usually approved at a fixed dose. However, oral tyrosine kinase inhibitors are characterized by a large intra and inter-individual pharmacokinetic variability, and a narrow therapeutic index. Hence, their prescription is hazardous and unsafe in non-selected people from daily clinical practice. The increasing number of available targeted therapies point out new challenges. These challenges should especially concern prescription for out of the ordinary patients, rules for ...
Source: Bulletin du Cancer - October 8, 2018 Category: Cancer & Oncology Authors: Zaibet S, Vauchier C, Khoudour N, Roulleaux Dugage M, Korb-Savoldelli V, Alexandre J, Blanchet B, Goldwasser F, Thomas-Schoemann A, Bellesoeur A Tags: Bull Cancer Source Type: research

Bevacizumab: Is the lower the better for glioblastoma patients in progression?
DISCUSSION: Use of bevacizumab at progression at lower than usual doses seems to give the same results as the standard dose without giving additional toxicity. PMID: 30301554 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - October 6, 2018 Category: Cancer & Oncology Authors: Sirven-Villaros L, Bourg V, Suissa L, Mondot L, Almairac F, Fontaine D, Paquis P, Burel-VandenBos F, Frenay M, Thomas P, Lebrun-Frenay C Tags: Bull Cancer Source Type: research

[Dermatofibrosarcoma: Management].
Abstract Dematofibrosarcoma protuberans (DFSP) are very rare (1 to 4 incident cases per million of inhabitants). The local spreading of DFSP is underestimated. The histological diagnosis is challenging but we now know a specific marker (translocation t(17;22)(q22;q13) (COL1A1;PDGFB)). The risk of metastatic relapse is low (and related to fibrosarcoma component); the risk of local relapse depends on the quality of surgery. Management of localized DFSP is based on large resection with meticulous analysis of margins (with or without Mohs microsurgery). Advanced stages not amenable to surgery or metastatic DFSP (with ...
Source: Bulletin du Cancer - October 5, 2018 Category: Cancer & Oncology Authors: Penel N, El Bedoui S, Robin YM, Decanter G Tags: Bull Cancer Source Type: research

[High-risk neuroblastoma treatment strategy: The experience of the SIOPEN group].
Abstract High-risk neuroblastoma comprises nearly half of cases of neuroblastoma and the long-term survival is less than 50% despite complex and intensive treatments. Studies conducted in Europe and in North America in the last two decades have identified a strategy based on four therapeutic phases: an intensive induction therapy, a local control by surgery and radiation, a consolidation phase with single or tandem high dose chemotherapy and autologous transplant, and immunotherapy to eliminate residual disease. Future treatment improvements are based on progress at each of these therapeutic steps and ultimately a...
Source: Bulletin du Cancer - October 2, 2018 Category: Cancer & Oncology Authors: Valteau-Couanet D, Schleiermacher G, Sarnacki S, Pasqualini C Tags: Bull Cancer Source Type: research

Consumption of processed and pickled food and esophageal cancer risk: A systematic review and meta-analysis.
In conclusion, this study suggests that both a high consumption of processed and pickled food may increase the EC risk. PMID: 30290976 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - October 2, 2018 Category: Cancer & Oncology Authors: Yan B, Zhang L, Shao Z Tags: Bull Cancer Source Type: research

[DNA damage repair: An emerging strategy in metastatic prostate cancer].
Abstract Genetic instability is one part of the oncogenic process. Gene mutations involved in DNA repair mechanisms can promote this genetic instability and participate in oncogenesis and metastatic progression. In prostate cancer, DNA repair abnormalities mainly correspond to somatic or constitutional mutations of the BRCA2 and ATM genes. Therapeutic management of metastatic castration-resistant prostate cancer (mCRPC) is currently based on new hormonal therapies (abiraterone, enzalutamide) and taxane-type chemotherapy (docetaxel or cabazitaxel). Preliminary data tend to indicate a specific activity of agents cau...
Source: Bulletin du Cancer - September 29, 2018 Category: Cancer & Oncology Authors: Loriot Y, Meynard G, Klajer E, Bolognini C, Gassian N, Thiery-Vuillemin A Tags: Bull Cancer Source Type: research

[Opioid switch and change of route of administration in cancer patients treated by morphine].
Abstract This paper reviewed the 2002 guidelines established by the National Federation of Cancer Centres. A group of experts nominated by the 3 French Societies involved in the treatment of cancer pain (AFSOS, SFAP, SFETD), established new guidelines ratios for morphine switching and/or changing of route of administration, in patients for whom either pain was not adequatly managed or adverse effects were unbearable. After a rapid reminder of the pharmacokinetics and metabolism properties of morphine, experts explained why the theory of opioid rotation (oxycodone, hydromorphone, fentanyl, methadone, tape...
Source: Bulletin du Cancer - September 28, 2018 Category: Cancer & Oncology Authors: Michenot N, Rostaing S, Baron L, Faure S, Jovenin N, Hubault P, Delorme T, Collin E, Filbet M, Chvetzoff G, Delorme C, Minello C, Magnet M, Ammar D, Krakowski I, Poulain P Tags: Bull Cancer Source Type: research

Bladder cancer knowledge in the Lebanese population: When ignorance could be harmful.
This study was designed to assess bladder cancer knowledge among the Lebanese population. Between November 2017 and January 2018, a cross-sectional study was directed, including patients and visitors of one of the largest university hospitals in the capital Beirut. A face-to-face questionnaire evaluated knowledge regarding, among others, the most important risk factor for bladder cancer and the most frequent revealing symptom. This survey also obtained information regarding smoking habits. A total of 701 participants completed the survey. A total of 49.1% were younger than 50 years, 56.3% were male, 56.6% had a college deg...
Source: Bulletin du Cancer - September 26, 2018 Category: Cancer & Oncology Authors: Souaid T, Hindy JR, Eid R, Kourie HR, Kattan J Tags: Bull Cancer Source Type: research

[The French Genetic and Cancer Consortium guidelines for multigene panel analysis in hereditary breast and ovarian cancer predisposition].
DISCUSSION: Due to the rapid increase in knowledge, the GGC has planned a yearly update of the bibliography to take into account new findings. Furthermore, genetic-epidemiological studies are being initiated to better estimate the cancer risk associated with genes which are not yet included in the HBOC diagnosis panel. PMID: 30268633 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - September 26, 2018 Category: Cancer & Oncology Authors: Moretta J, Berthet P, Bonadona V, Caron O, Cohen-Haguenauer O, Colas C, Corsini C, Cusin V, De Pauw A, Delnatte C, Dussart S, Jamain C, Longy M, Luporsi E, Maugard C, Nguyen TD, Pujol P, Vaur D, Andrieu N, Lasset C, Noguès C, Groupe génétique et cancer Tags: Bull Cancer Source Type: research

Knockdown of miR-299-5p inhibits the progression of hepatocellular carcinoma by targeting SIAH1.
CONCLUSIONS: MiR-299-5p knockdown suppressed the progression of HCC by targeting SIAH1, highlighting its role as a potential biomarker and therapeutic target of HCC. PMID: 30266288 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - September 25, 2018 Category: Cancer & Oncology Authors: Jiang X, Shen X Tags: Bull Cancer Source Type: research

[Data from the AACR 2018 meeting on the combination chimio-immunotherapy on advanced non-small cells lung cancer (NSCLC)].
lez M PMID: 30262415 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - September 24, 2018 Category: Cancer & Oncology Authors: Simonneau Y, Ruppert AM, Chaabane N, Lavolé A, Wislez M Tags: Bull Cancer Source Type: research

[Chemotherapy-induced peripheral neuropathy: Symptomatology and epidemiology].
lla V Abstract Chemotherapy-induced peripheral neuropathy (CIPN) is common with specific semiological characteristics. When CIPN appears, there are many difficulties in guaranteeing sustained treatment, especially with optimal protocol. Moreover, CIPN have bad repercussions on quality of life after cancer disease. In this article, we have achieved a current state of CIPN and try to report details about semiological characteristics and topography. We have also produced some epidemiological data. Nonetheless, we have not voluntarily introduced treatment because it will be the topic of further work. PMID: 302449...
Source: Bulletin du Cancer - September 20, 2018 Category: Cancer & Oncology Authors: Kerckhove N, Collin A, Condé S, Chaleteix C, Pezet D, Balayssac D, Guastella V Tags: Bull Cancer Source Type: research

[Physiopathological mechanisms of immune-related adverse events induced by anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies in cancer treatment].
Abstract Recently, the emergence of anti-CTLA-4 and anti-PD-1/PD-L1 antibodies called immune check-point inhibitors (ICPI) has modified the landscape of anti-cancer treatments. These therapeutics are associated with immune related adverse events that affect many organs, most commonly skin, digestive tract, endocrine glands and lungs. This review summarizes the main physiopathological hypotheses on the mechanisms of these toxicities. In most cases, the T lymphocytes hyperactivation induced by ICPI generates a specific response directed against tumor antigens, leading to anti-tumor activity in tumor tissues but also...
Source: Bulletin du Cancer - September 20, 2018 Category: Cancer & Oncology Authors: Passat T, Touchefeu Y, Gervois N, Jarry A, Bossard C, Bennouna J Tags: Bull Cancer Source Type: research

[Medico-economic benefits of subcutaneous formulations of trastuzumab and rituximab in day hospitalisation (SCuBA Study)].
The objective of this study was to evaluate the medical and economic consequences of switching to subcutaneous formulations of trastuzumab and rituximab. METHODS: Thirty-six day care units in 30 hospitals or clinics participated in this observational study. Data were collected on the capacity of the units, the number of chemotherapy sessions implemented, the duration of occupation of a chair and the production capacity of the unit pharmacy. The number of additional sessions made possible by the use of subcutaneous forms in 2016 was determined and the associated gain in earnings calculated using national tariffs. ...
Source: Bulletin du Cancer - September 20, 2018 Category: Cancer & Oncology Authors: Favier M, Le Goc-Sager F, Vincent-Cantini I, Launay V, Giroux EA, Lièvremont K, Bonnet I, Barbe C, Duval E, Loric N, Delbaldo C Tags: Bull Cancer Source Type: research

[Le Bulletin du Cancer: Developing adult - children partnership].
PMID: 30243476 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - September 19, 2018 Category: Cancer & Oncology Authors: Gandemer V, Orbach D, Pellier I Tags: Bull Cancer Source Type: research

[Minimal residual disease in chronic lymphocytic leukemia: A still current issue in 2018].
Abstract Minimal residual disease (MRD) is widely used in oncohematology. In chronic lymphocytic leukemia (CLL), it can be measured by flow cytometry or polymerase chain reaction and is getting a greater place, owing to the dramatic therapeutic advances in the management this disease. As MRD decrease after chemoimmunotherapy is associated with improved progression free and overall survivals, its measure is now recommended as a surrogate marker for cytotoxic drugs licensures. This association is independent from treatment received and raises a few questions, such as sequential MRD measures to stop treatment in case...
Source: Bulletin du Cancer - September 19, 2018 Category: Cancer & Oncology Authors: Gauthier M, Comont T, Vergez F, Ysebaert L Tags: Bull Cancer Source Type: research

Precision medicine and bladder cancer heterogeneity.
Abstract Bladder cancer is a widespread and highly heterogeneous malignancy. Moreover, bladder cancer recurrence and treatment failure are common, making this disease a challenge for genito-urinary surgeons. Precision medicine represents a new medical concept and model. It is based on personalized medicine, and employs genomics, proteomics, and other omics and cutting-edge medical technologies to classify disease at the molecular level, enabling accurate identification of its cause and therapeutic targets, ultimately offering precise, personalized medicine. The existence of heterogeneity in bladder cancer, resulti...
Source: Bulletin du Cancer - September 19, 2018 Category: Cancer & Oncology Authors: Ma G, Yang X, Liang Y, Wang L, Li D, Chen Y, Liang Z, Wang Y, Niu H Tags: Bull Cancer Source Type: research

[How to predict the relapse after surgery or radiofrequency of liver metastases of colorectal cancer? Interest of the serum kinetic variation of a matrix metalloproteinase cluster].
CONCLUSION: This is the first study wich correlates the post-operative level of 4 MMPs and TIMP-1 with the risk of liver recurrence after surgery or radiofrequency. Serum TIMP-1 level at J0 could be helpful to identify patients with higher risk but these results need to be confirmed in a large-scale study. PMID: 30243479 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - September 19, 2018 Category: Cancer & Oncology Authors: Frenoux C, Rebischung C, Quesada JL, Mendosa C, Letoublon C, Trocmé C Tags: Bull Cancer Source Type: research

[Metastatic stomach cancer: Clinical trials in Asia and in Occident].
Abstract Although cytotoxic chemotherapy is the main therapeutic option to treat gastric cancer in the metastatic setting, molecular targeted agents have recently been introduced in an effort to improve survival outcomes which in average do not exceed 1 year. Trastuzumab and ramucirumab, antibodies directed against HER2 and VEGFR2, respectively, may provide clinical benefit for some patients. Results of clinical studies show that Asian patients have increased survival compared to Caucasian patients. Differences between populations, and in particular the presence of polymorphisms capable of influencing the ava...
Source: Bulletin du Cancer - September 19, 2018 Category: Cancer & Oncology Authors: Bui QL, Grazziotin-Soares D, Hasiniatsy RE, Trinh HS, Richard S, Lotz JP, Gligorov J, Khalil A Tags: Bull Cancer Source Type: research

[Adjuvant chemotherapy for upper tract urothelial cancer: Level of evidence IA].
PMID: 30236478 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - September 17, 2018 Category: Cancer & Oncology Authors: Pannier D, Fantoni JC, Turpin A, Penel N Tags: Bull Cancer Source Type: research

[CAR T cells: Current indications in children and perspectives].
hel A Abstract Acute lymphoblastic leukemia (ALL) is the first cause of cancer in children. Five-year overall survival is greater than 90% but leukemia remains a major cause of death from cancer in children. A new class of immunotherapy based on a chimeric antigen receptor "CAR" targeting the CD19 on the B leukemic cells and that is transduced in an autologous or allogenic T lymphocyte will allow to transform the prognosis of refractory or relapsed B-ALL. Overall response rates range from 60 to 90% in phase I-II studies in patients with second relapse or more or with refractory disease. Persistent remiss...
Source: Bulletin du Cancer - September 17, 2018 Category: Cancer & Oncology Authors: Dourthe MÉ, Yakouben K, Chaillou D, Lesprit E, Dalle JH, Baruchel A Tags: Bull Cancer Source Type: research

[Management of uveal melanomas, guidelines for oncologists].
Abstract Uveal melanomas are the most frequent primary malignant eye tumor. Enucleation was historically the gold standard. Since then, several studies showed that conservative treatments did not increase the risk of metastasis or survival. Choroidal melanomas are both radioresistant and located close to visual structures (the optic nerve and macula) of the eye, which may be preserved in some settings without compromising tumor control, as this is the first priority. Different types of radiation therapy may be used for such tumors: brachytherapy and charged particles, including proton beam therapy. If visual progn...
Source: Bulletin du Cancer - September 11, 2018 Category: Cancer & Oncology Authors: Mathis T, Cassoux N, Tardy M, Piperno S, Gastaud L, Dendale R, Maschi C, Nguyen AM, Meyer L, Bonnin N, Baillif S, Tick S, Mouriaux F, Jaspart F, Dellis J, Rosier L, Desjardins L, Herault J, Caujolle JP, Thariat J Tags: Bull Cancer Source Type: research

[Smoking and alcohol cessation programs in patients with head and neck cancer].
er Denois V Abstract Most head and neck cancers are associated with smoking and alcohol exposure. Smoking and alcohol cessation (ASC) is associated with improved quality of life, cancer therapy efficacy, decreased treatment-related and cardiovascular risks, and is expected to decrease the risk of second primary tumor. It is therefore a high priority in the plan of care. However, results of current ASC programs are disappointing and understanding the reasons of this is critical. We started a qualitative study in 6 academic centers including 3 university hospitals, one regional hospital and one comprehensive cancer ...
Source: Bulletin du Cancer - September 7, 2018 Category: Cancer & Oncology Authors: Hamant C, Deneuve S, Albaret MA, Zrounba P, Breton P, Céruse P, Gleizal A, Alix T, Bettega G, Chauvin F, Saintigny P, Régnier Denois V Tags: Bull Cancer Source Type: research

[Autopsy of an expert consensus. To end hyperthermic intraperitoneal chemotherapy in colorectal carcinomatosis].
PMID: 30173868 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - August 30, 2018 Category: Cancer & Oncology Authors: Evrard S Tags: Bull Cancer Source Type: research

[Genealogy of lymph node and visceral metastases in colorectal cancer: "sisters" or "cousins"?]
[Genealogy of lymph node and visceral metastases in colorectal cancer: "sisters" or "cousins"?] Bull Cancer. 2018 Aug 24;: Authors: Vibert J, Rousseau B PMID: 30149945 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - August 24, 2018 Category: Cancer & Oncology Authors: Vibert J, Rousseau B Tags: Bull Cancer Source Type: research

[How to manipulate DNA repair to generate neoantigens and ameliorate the efficacy of immunotherapies].
PMID: 30146085 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - August 23, 2018 Category: Cancer & Oncology Authors: Pourquier P Tags: Bull Cancer Source Type: research

[Adaptive designs for innovative therapies assessment: New methodological challenges].
PMID: 30146086 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - August 23, 2018 Category: Cancer & Oncology Authors: Asselain B Tags: Bull Cancer Source Type: research

Methylation analysis for multiple gene promoters in non-small cell lung cancers in high indoor air pollution region in China.
CONCLUSIONS: A panel of genes including CDKN2A, DLEC1, CDH1, DAPK and RUNX3 may be used as potential epigenetic biomarkers for early lung cancer detection. CDH1 promoter methylation was associated with lung cancer metastasis in areas of air pollution from buring of smoky coals. DLEC1 and CDH1 exhibited specific high methylation frequencies, different from previous reports. PMID: 30126609 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - August 17, 2018 Category: Cancer & Oncology Authors: Huang X, Wu C, Fu Y, Guo L, Kong X, Cai H Tags: Bull Cancer Source Type: research

[Proton therapy in soft tissue and bone sarcomas].
Abstract Sarcomas are a common type of tumor within the pediatric population. The utilization of proton therapy as a primary attribute the ability to spare adjacent healthy tissue, therefore, proton therapy has become a preferential indication in pediatrics compared to other photon irradiation modalities. Proton therapy is also a proven and historically validated irradiation technique in the treatment of chondrosarcomas and chordomas of the skull base and spine. Additionally, proton therapy can potentially limit irradiated healthy tissue volumes in adults and limit the risk of acute and late toxicities. The evalua...
Source: Bulletin du Cancer - August 17, 2018 Category: Cancer & Oncology Authors: Thariat J, Tessonnier T, Bonvalot S, Lerouge D, Mammar H, Bolle S, Claren A, Duffaud F, Alapetite C, Vogin G Tags: Bull Cancer Source Type: research

[The CAR-T cells are here].
Abstract Due to immunotherapy, a new era of treatment is opening up for the treatment of solid cancers and hematological tumors. T cells genetically modified with a chimeric antigen receptor (CAR-T cells) have recently been proved efficient in hematological malignancies expressing CD19. On June 20th 2018, the European Medicines Agency gave a favorable opinion on two types of anti-CD19 CAR-T cells - tisagenlecleucel and axicabtagène ciloleucel - in the management of malignant hemopathies B after two lines of treatment. Their remarkable efficacy has been demonstrated in the first clinical ...
Source: Bulletin du Cancer - August 14, 2018 Category: Cancer & Oncology Authors: Croizier C, Douge A, Bay JO, Lemal R Tags: Bull Cancer Source Type: research

[Reprint of: Treatment of patients with inoperable stage III or stage IV melanoma. Soci été française de dermatologie].
[Reprint of: Treatment of patients with inoperable stage III or stage IV melanoma. Société française de dermatologie]. Bull Cancer. 2018 Aug 13;: Authors: Guillot B, Charles J, Jeudy G, Cupissol D, Dupuy A, Dutriaux C, Gangloff D, Magne N, Mirabel X, M'Sadek A, Pracht M, Sichel C, Do Outeiro G PMID: 30115366 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - August 13, 2018 Category: Cancer & Oncology Authors: Guillot B, Charles J, Jeudy G, Cupissol D, Dupuy A, Dutriaux C, Gangloff D, Magne N, Mirabel X, M'Sadek A, Pracht M, Sichel C, Do Outeiro G Tags: Bull Cancer Source Type: research

[5-fluorouracil therapeutic drug monitoring: Update and recommendations of the STP-PT group of the SFPT and the GPCO-Unicancer].
Abstract Despite being 60-years old now, 5-FU remains the backbone of numerous regimen to treat a variety of solid tumors such as breast, head-and-neck and digestive cancers either in neo-adjuvant, adjuvant or metastatic settings. Standard 5-FU usually claims 15-40% of severe toxicities and up to 1% of toxic-death. Numerous studies show a stiff relationship between 5-FU exposure and toxicity or efficacy. In addition, 5-FU pharmacokinetics is highly variable between patients. Indeed, 80% of the 5-FU dose is catabolized in the liver by dihydropyrimidine dehydrogenase (DPD) into inactive compounds. It is now well est...
Source: Bulletin du Cancer - August 10, 2018 Category: Cancer & Oncology Authors: Lemaitre F, Goirand F, Launay M, Chatelut E, Boyer JC, Evrard A, Paludetto MN, Guilhaumou R, Ciccolini J, Schmitt A Tags: Bull Cancer Source Type: research

[Medical treatment of small cell lung cancer: Can we leave the area of cisplatin-etoposide?]
Abstract Small cell lung cancer accounts for 14% of all lung cancers. It remains a major challenge for oncology as the progresses made in the past three decades are modest. After a rapid overview of current knowledge regarding somatic genomic alterations, this state-of-art addresses pathways to improve small-cell lung cancer outcome such as the targeting of DNA damage repair mechanisms firstly anti-PARPs, inhibitory molecules of EZH2, derepression of the NOTCH pathway, rovalbituzumab-tesirine, inhibition of serine/threonine Aurora A kinase, temozolomide and its dependence on methylation of the MGMT promoter. This ...
Source: Bulletin du Cancer - August 9, 2018 Category: Cancer & Oncology Authors: Pujol JL, Roch B, Pujol CN, Goze C Tags: Bull Cancer Source Type: research

[Supportive care for survivors].
This article aims to review the facilitators and obstacles of this perspective. PMID: 30097280 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - August 7, 2018 Category: Cancer & Oncology Authors: Ninot G, Debourdeau P, Blanc-Legier F, De Crozals F, De Rauglaudre G, Khouri S, Kirscher S, Mineur L, Piollet I, Sant I, Schillinger P, Serin D Tags: Bull Cancer Source Type: research

[Integrated podiatrist care for prostate cancer patients treated with docetaxel: Feasibility and results].
CONCLUSION: The integration of podiatrist care is feasible in routine cancer care and can help improving the management of docetaxel-induced nail toxicity in metastatic prostate cancer patients. PMID: 30078546 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - August 2, 2018 Category: Cancer & Oncology Authors: Chabanol H, Huillard O, Prin L, Villeminey C, Rondeau A, Boudou-Rouquette P, Astorg F, Musenghesi B, Du Mortier C, Alexandre J, Goldwasser F Tags: Bull Cancer Source Type: research

Small cell carcinoma of the endometrium: A clinicopathological study and management of three cases.
Abstract Endometrial small cell carcinoma (ESCC) is an extremely rare and aggressive tumor with poor prognosis. It is characterized by early regional and systemic spread leading to rapid development of lymph nodes, pelvic and extrapelvic metastasis and compromising the outcome. In this paper, we reported three cases of ESCC confirmed by pathological and immunohistochemistry studies. In one case, ESCC was associated with endometrioid carcinoma and carcinosarcoma, while the other two cases were pure ESCC. Two cases were diagnosed at early stage IA of the International Federation of Gynecology and Obstetrics (FIGO) c...
Source: Bulletin du Cancer - July 26, 2018 Category: Cancer & Oncology Authors: Sidibe FM, Traore Z, Georgala A, Kanab R, Larsimont D, Awada A, Piccart-Gebhart M Tags: Bull Cancer Source Type: research

[Impacts of routine patient-reported-outcomes monitoring in oncology].
dé N PMID: 30032955 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - July 19, 2018 Category: Cancer & Oncology Authors: Fiteni F, Favier M, Bascoul-Mollevi C, Gourgou S, Cousin C, Houédé N Tags: Bull Cancer Source Type: research

[MBD4 inactivation induces a new mutator phenotype in cancers].
PMID: 30032956 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - July 19, 2018 Category: Cancer & Oncology Authors: Rodrigues M, Mobuchon L, Houy A, Derrien AC, Stern MH Tags: Bull Cancer Source Type: research

[Maintenance strategies for advanced pancreatic cancer: Rationale and issues].
PMID: 30029762 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - July 17, 2018 Category: Cancer & Oncology Authors: Turpin A, Chevalier H, Neuzillet C Tags: Bull Cancer Source Type: research

[An analysis of breast cancer treatment waiting times: Experience of a tertiary referral center in Morocco].
Abstract Measuring waiting times is a good indicator of quality and performance of cancer care. However, no detailed evaluation of these deadlines has been carried out in Morocco. The aim of this study was to determine the waiting times of medical care of breast cancer in a national tertiary referral center. The study was carried out by retrospective analysis of 373 cases of patients randomly selected among the cases recruited during the year 2015. Twelve delays of the care pathway were evaluated. The mean age was of 50,7 years. The deadline of access to this center was 9±8days. The deadline of access to th...
Source: Bulletin du Cancer - July 10, 2018 Category: Cancer & Oncology Authors: Mimouni M, Chaouki W, Errihani H, Benjaafar N Tags: Bull Cancer Source Type: research

[Fluoropyrimidines cardiac toxicity: 5-fluorouracil, capecitabine, compound S-1 and trifluridine/tipiracil].
ada D Abstract The incidence of cardiac toxicity of 5-flurorouracil (5-FU) IV and capecitabine varies from 1.2 to 18%. The physiopathology of this toxicity is still under study, various hypotheses are mentioned. In the absence of identified prophylactic treatment, reintroduction of this cytotoxic is at risk. A discussion between oncologists and cardiologists is essential to estimate the balance between benefit and risk and the careful reintroduction of treatment. An alternative compound might be raltitrexed which is currently the treatment recommended in case of intolerance to fluoropyrimidines. The compound S-1 d...
Source: Bulletin du Cancer - June 27, 2018 Category: Cancer & Oncology Authors: Vaflard P, Ederhy S, Torregrosa C, André T, Cohen R, Lopez-Trabada D Tags: Bull Cancer Source Type: research

[What role for the direct oral anticoagulants in oncology?]
PMID: 29960639 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - June 27, 2018 Category: Cancer & Oncology Authors: Lebellec L, Kouakam C, Bertrand N, Penel N Tags: Bull Cancer Source Type: research

[Comparative costs study between ready-to-administer bag of gemcitabine and production in reconstitution unit].
DISCUSSION: Ready-to-administer bags of gemcitabine allow relevant coverage of manufacturing doses. The annual extra cost would reach 37,200€ for our establishment. But, it can be justified by expected benefits: safer medication circuit, saving time of pharmacy technician…. PMID: 29958654 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - June 26, 2018 Category: Cancer & Oncology Authors: Pouplin M, Lortal B Tags: Bull Cancer Source Type: research

[Genomic characterization of head and neck squamous cell carcinoma: Impact and challenges for therapeutic management].
Abstract Squamous cell carcinomas are the most frequent subgroup among head and neck malignant tumors (HNSCC). Tobacco (±alcohol) and HPV infection, the two main risk factors, define two entities with distinct anatomo-clinical and genetic features. HPV-positive, non-tobacco-related HNSCCs are associated with a better prognosis, a rather simple genomic profile, frequent activating mutations of genes involved in pi3kinase-pathway, and the scarcity of mutations of tumor suppressor genes. HPV-negative, tobacco-related HNSCC are genetically more complex, are characterized by almost mandatory inactivating mutatio...
Source: Bulletin du Cancer - June 21, 2018 Category: Cancer & Oncology Authors: Saada-Bouzid E, Milano G, Thariat J Tags: Bull Cancer Source Type: research

R éponse à Braillon et Taiebi.
Réponse à Braillon et Taiebi. Bull Cancer. 2018 Jun 21;: Authors: de Nonneville A, Gonçalves A PMID: 29937335 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - June 21, 2018 Category: Cancer & Oncology Authors: de Nonneville A, Gonçalves A Tags: Bull Cancer Source Type: research

[Early postsurgical temozolomide treatment in newly diagnosed bad prognosis glioblastoma patients: Feasibility study].
CONCLUSION: Early postsurgical temozolomide treatment prior to standard adjuvant therapy for poor prognosis glioblastoma patients in our small prospective series presents toxicity and survival similar to those published in the literature for the general population of glioblastoma. These encouraging results should be confirmed by a multicentric study comparing this regiment with the standard treatment. PMID: 29937336 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - June 21, 2018 Category: Cancer & Oncology Authors: Chaskis E, Luce S, Goldman S, Sadeghi N, Melot C, De Witte O, Devriendt D, Lefranc F Tags: Bull Cancer Source Type: research

[Prescription in oncology: Homeopathy or psychotherapies and nicotine substitutes?]
PMID: 29935913 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - June 20, 2018 Category: Cancer & Oncology Authors: Braillon A, Taiebi F Tags: Bull Cancer Source Type: research

[Definitions of oligometastatic disease and new treatment concepts].
Abstract The definition of oligometastatic disease has evolved into distinct intermediate stages of different prognosis between single metastasis and polymetastatic disease. We assessed the therapeutic impact of such clinical definitions based on a review of the literature. Increasingly advanced stages of the metastatic disease with some prominent oligometastatic targets can be treated with stereotactic irradiation with ablative intent owing to its excellent tolerance profile. Used in different settings, metastatic ablation can either prolong progression free survival, delay change of systemic therapy or delay the...
Source: Bulletin du Cancer - June 20, 2018 Category: Cancer & Oncology Authors: Kissel M, Helou J, Thariat J Tags: Bull Cancer Source Type: research

[Immune checkpoints inhibitors: Recent data from ASCO's meeting 2017 and perspectives].
Abstract Immune checkpoint inhibitors anti-PD-1, anti-PD-L1 and anti-CTLA-4 have been in development in several indications and have changed the face of cancer patients' management. Cancer immunotherapy was central in ASCO's meeting 2017. The identification of patients who could benefit most from immune checkpoint inhibitors is essential. The predictive value of PD-L1 status remains insufficient to select patients who could respond to immunotherapy. An extended search for new biomarkers predictive of response (INF-γ, mutational load) is ongoing, in order to better select responders. Immune checkpoint inhibit...
Source: Bulletin du Cancer - June 19, 2018 Category: Cancer & Oncology Authors: Kfoury M, Disdero V, Vicier C, Le Saux O, Gougis P, Sajous C, Vignot S Tags: Bull Cancer Source Type: research